华熙生物(688363)

净利润 + 每股收益

Created with Highcharts 9.1.0

09-3006-3003-3112-3102.557.500.61.21.8

净利润(亿元) 每股收益(元)

    截至第三季度实现净利润3.59亿元，每股收益0.75元。

股东权益 + 未分配利润

Created with Highcharts 9.1.0

09-3006-3003-3112-31025507524262830

股东权益(亿元) 未分配利润(亿元)

    截至第三季度最新股东权益705320.93万元，未分配利润263413.07万元。

总资产 + 负债

Created with Highcharts 9.1.0

09-3006-3003-3112-31040801208121620

总资产(亿元) 负债(亿元)

    截至第三季度最新总资产868796.20万元，负债163475.27万元。

利润表 报告期2024-09-302024-06-302024-03-312023-12-31营业总收入3,874,744,443.182,810,742,396.151,360,531,9156,075,923,853.74营业总成本3,419,165,826.772,368,091,581.711,042,739,955.345,438,234,078.17营业利润436,124,755.33416,279,478.8300,319,112.92708,385,550.59利润总额436,569,109.98417,411,890.71300,604,668.35701,722,462.64净利润359,049,886.13340,504,211.44243,387,652.32582,742,033.51其他综合收益-1,856,452.6-10,234,829.2-9,119,542.0628,665,320.95综合收益总额357,193,433.53330,269,382.24234,268,110.26611,407,354.46 资产负债表 报告期2024-09-302024-06-302024-03-312023-12-31流动资产合计2,682,481,539.482,749,004,006.512,839,514,084.843,122,855,256.25非流动资产合计6,005,480,452.745,867,092,015.435,475,876,773.315,347,153,037.58资产总计8,687,961,992.228,616,096,021.948,315,390,858.158,470,008,293.83流动负债合计1,136,227,866.531,198,715,597.05902,649,364.261,220,791,687.05非流动负债合计498,524,864.01395,571,882.1285,408,577.8265,789,863.44负债合计1,634,752,730.541,594,287,479.151,188,057,942.061,486,581,550.49归属于母公司股东权益合计7,018,771,164.376,985,657,844.567,087,986,444.986,944,100,603.15股东权益合计7,053,209,261.687,021,808,542.797,127,332,916.096,983,426,743.34负债和股东权益合计8,687,961,992.228,616,096,021.948,315,390,858.158,470,008,293.83 现金流量表 报告期2024-09-302024-06-302024-03-312023-12-31经营活动现金流入小计4,179,095,693.682,927,684,098.921,380,453,113.826,820,494,614.69经营活动现金流出小计3,905,039,429.412,663,061,577.611,345,601,845.616,120,846,413.47经营活动产生的现金流量净额274,056,264.27264,622,521.3134,851,268.21699,648,201.22投资活动现金流入小计647,652,292.35596,133,392.53342,138,879.041,806,347,467.51投资活动现金流出小计953,744,001.24796,708,156.78397,083,821.512,419,229,490.98投资活动产生的现金流量净额-306,091,708.89-200,574,764.25-54,944,942.47-612,882,023.47筹资活动现金流入小计100,000,000--57,714,817.58筹资活动现金流出小计449,700,503.76251,465,402.19220,205,324.86585,281,313.67筹资活动产生的现金流量净额-349,700,503.76-251,465,402.19-220,205,324.86-527,566,496.09汇率变动对现金及现金等价物的影响3,481,744.29-2,081,853.33-1,528,348.1510,564,999.38现金及现金等价物净增加额-378,254,204.09-189,499,498.46-241,827,347.27-430,235,318.96期末现金及现金等价物余额434,805,777.91623,560,483.54571,232,634.73813,059,982

最新报告期：2024-11-27

研究机构分析师预测每股收益(元)更新日2024年2025年2026年中信证券徐晓芳,杜一帆0.851.031.272024-11-27长江证券李锦,罗祎1.051.531.872024-11-17国元证券李典1.041.471.792024-11-04中信证券徐晓芳,杜一帆0.851.031.272024-11-01民生证券刘文正,解慧新1.061.552.072024-11-01

网址：华熙生物(688363) https://mxgxt.com/news/view/238147

相关内容

干货！2022年中国药妆行业龙头企业分析——华熙生物：底层科技支撑产品制造
华熙生物董秘回复：公司高度重视明星大单品的打造。明星大单品的策略具备更高的投入产出比，同时可以带动新产品销售，更有利于与用户建立深度情感链接，是传播品牌力的有形载体。2021年度，四大品牌均打造出各自核心爆款产品（明星大单品）及衍生系列，包
华熙生物的困局，赵燕的心病
华熙生物风波背后：如何避免网红员工与企业博弈？
QFII抱团股出炉 六家扎堆买入乐普医疗 三家新进华熙生物（名单）
戴着与罗云熙的定情信物…
把非遗文化带回家！深圳翰熙古陶瓷博物馆开展体验非遗拓印DIY活动
王一博也带不动？乐华娱乐艺人管理收入首次下滑，杜华入局直播带货
他是演员罗云熙@罗云熙Leo ，以坚韧的精神书写演绎的华章！
康熙宫廷西洋画家所绘《康熙大帝肖像》来华展出

随便看看